159 related articles for article (PubMed ID: 20228830)
21. Characterization of mibefradil block of the human heart delayed rectifier hKv1.5.
Perchenet L; Clément-Chomienne O
J Pharmacol Exp Ther; 2000 Nov; 295(2):771-8. PubMed ID: 11046117
[TBL] [Abstract][Full Text] [Related]
22. Effects of (-)-epigallocatechin-3-gallate, the main component of green tea, on the cloned rat brain Kv1.5 potassium channels.
Choi BH; Choi JS; Min DS; Yoon SH; Rhie DJ; Jo YH; Kim MS; Hahn SJ
Biochem Pharmacol; 2001 Sep; 62(5):527-35. PubMed ID: 11585049
[TBL] [Abstract][Full Text] [Related]
23. Characterization of human cardiac Kv1.5 inhibition by the novel atrial-selective antiarrhythmic compound AVE1231.
Ehrlich JR; Ocholla H; Ziemek D; Rütten H; Hohnloser SH; Gögelein H
J Cardiovasc Pharmacol; 2008 Apr; 51(4):380-7. PubMed ID: 18427281
[TBL] [Abstract][Full Text] [Related]
24. Serum albumin attenuates the open-channel blocking effects of propofol on the human Kv1.5 channel.
Kojima A; Bai JY; Ito Y; Ding WG; Kitagawa H; Matsuura H
Eur J Pharmacol; 2016 Jul; 783():117-26. PubMed ID: 27164421
[TBL] [Abstract][Full Text] [Related]
25. Inhibition by nystatin of Kv1.3 channels expressed in Chinese hamster ovary cells.
Hahn SJ; Wang LY; Kaczmarek LK
Neuropharmacology; 1996; 35(7):895-901. PubMed ID: 8938720
[TBL] [Abstract][Full Text] [Related]
26. Inhibitory effects of hesperetin on Kv1.5 potassium channels stably expressed in HEK 293 cells and ultra-rapid delayed rectifier K(+) current in human atrial myocytes.
Wang H; Wang HF; Wang C; Chen YF; Ma R; Xiang JZ; Du XL; Tang Q
Eur J Pharmacol; 2016 Oct; 789():98-108. PubMed ID: 27397430
[TBL] [Abstract][Full Text] [Related]
27. The anchoring protein SAP97 retains Kv1.5 channels in the plasma membrane of cardiac myocytes.
Abi-Char J; El-Haou S; Balse E; Neyroud N; Vranckx R; Coulombe A; Hatem SN
Am J Physiol Heart Circ Physiol; 2008 Apr; 294(4):H1851-61. PubMed ID: 18245566
[TBL] [Abstract][Full Text] [Related]
28. Posttranslational modification of voltage-dependent potassium channel Kv1.5: COOH-terminal palmitoylation modulates its biological properties.
Jindal HK; Folco EJ; Liu GX; Koren G
Am J Physiol Heart Circ Physiol; 2008 May; 294(5):H2012-21. PubMed ID: 18344374
[TBL] [Abstract][Full Text] [Related]
29. Regulation of human cardiac Kv1.5 channels by extracellular acidification.
Wang S; Ding WG; Bai JY; Toyoda F; Wei MJ; Matsuura H
Pflugers Arch; 2016 Nov; 468(11-12):1885-1894. PubMed ID: 27796577
[TBL] [Abstract][Full Text] [Related]
30. Characterization of a novel Kv1.5 channel blocker in Xenopus oocytes, CHO cells, human and rat cardiomyocytes.
Bachmann A; Gutcher I; Kopp K; Brendel J; Bosch RF; Busch AE; Gögelein H
Naunyn Schmiedebergs Arch Pharmacol; 2001 Nov; 364(5):472-8. PubMed ID: 11692231
[TBL] [Abstract][Full Text] [Related]
31. Voltage gated K+ channel expression in arteries of Wistar-Kyoto and spontaneously hypertensive rats.
Cox RH; Fromme SJ; Folander KL; Swanson RJ
Am J Hypertens; 2008 Feb; 21(2):213-8. PubMed ID: 18174882
[TBL] [Abstract][Full Text] [Related]
32. Effects of anorexinogen agents on cloned voltage-gated K(+) channel hKv1.5.
Perchenet L; Hilfiger L; Mizrahi J; Clément-Chomienne O
J Pharmacol Exp Ther; 2001 Sep; 298(3):1108-19. PubMed ID: 11504808
[TBL] [Abstract][Full Text] [Related]
33. Inhibitory effects of cholinesterase inhibitor donepezil on the Kv1.5 potassium channel.
Li K; Cheng N; Li XT
Sci Rep; 2017 Feb; 7():41509. PubMed ID: 28198801
[TBL] [Abstract][Full Text] [Related]
34. miR-1 is increased in pulmonary hypertension and downregulates Kv1.5 channels in rat pulmonary arteries.
Mondejar-Parreño G; Callejo M; Barreira B; Morales-Cano D; Esquivel-Ruiz S; Moreno L; Cogolludo A; Perez-Vizcaino F
J Physiol; 2019 Feb; 597(4):1185-1197. PubMed ID: 29717493
[TBL] [Abstract][Full Text] [Related]
35. Calcineurin-independent inhibition of KV1.3 by FK-506 (tacrolimus): a novel pharmacological property.
Ahn HS; Kim SE; Choi BH; Choi JS; Kim MJ; Rhie DJ; Yoon SH; Jo YH; Kim MS; Sung KW; Kwon OJ; Hahn SJ
Am J Physiol Cell Physiol; 2007 May; 292(5):C1714-22. PubMed ID: 17166943
[TBL] [Abstract][Full Text] [Related]
36. New screening system for selective blockers of voltage-gated K(+) channels using recombinant cell lines dying upon single action potential.
Fujii M; Hayashi K; Ohya S; Yamamura H; Imaizumi Y
J Pharmacol Sci; 2013; 123(2):147-58. PubMed ID: 24096832
[TBL] [Abstract][Full Text] [Related]
37. Fluoxetine blocks cloned neuronal A-type K+ channels Kv1.4.
Choi BH; Choi JS; Ahn HS; Kim MJ; Rhie DJ; Yoon SH; Min DS; Jo YH; Kim MS; Hahn SJ
Neuroreport; 2003 Dec; 14(18):2451-5. PubMed ID: 14663209
[TBL] [Abstract][Full Text] [Related]
38. The human ether-a'-go-go related gene (hERG) K+ channel blockade by the investigative selective-serotonin reuptake inhibitor CONA-437: limited dependence on S6 aromatic residues.
Alexandrou AJ; Milnes JT; Sun SZ; Fermini B; Kim SC; Jenkinson S; Leishman DJ; Witchel HJ; Hancox JC; Leaney JL
J Physiol Pharmacol; 2014 Aug; 65(4):511-23. PubMed ID: 25179083
[TBL] [Abstract][Full Text] [Related]
39. Effects of the atrial antiarrhythmic drug AVE0118 on cardiac ion channels.
Gögelein H; Brendel J; Steinmeyer K; Strübing C; Picard N; Rampe D; Kopp K; Busch AE; Bleich M
Naunyn Schmiedebergs Arch Pharmacol; 2004 Sep; 370(3):183-92. PubMed ID: 15340774
[TBL] [Abstract][Full Text] [Related]
40. Inhibition of the cloned delayed rectifier K+ channels, Kv1.5 and Kv3.1, by riluzole.
Ahn HS; Choi JS; Choi BH; Kim MJ; Rhie DJ; Yoon SH; Jo YH; Kim MS; Sung KW; Hahn SJ
Neuroscience; 2005; 133(4):1007-19. PubMed ID: 15964489
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
